全文获取类型
收费全文 | 48143篇 |
免费 | 3659篇 |
国内免费 | 463篇 |
专业分类
耳鼻咽喉 | 147篇 |
儿科学 | 735篇 |
妇产科学 | 988篇 |
基础医学 | 6228篇 |
口腔科学 | 834篇 |
临床医学 | 4297篇 |
内科学 | 7916篇 |
皮肤病学 | 574篇 |
神经病学 | 6463篇 |
特种医学 | 881篇 |
外科学 | 4315篇 |
综合类 | 731篇 |
一般理论 | 4篇 |
预防医学 | 2030篇 |
眼科学 | 492篇 |
药学 | 11596篇 |
2篇 | |
中国医学 | 656篇 |
肿瘤学 | 3376篇 |
出版年
2023年 | 1834篇 |
2022年 | 2173篇 |
2021年 | 2475篇 |
2020年 | 3067篇 |
2019年 | 2048篇 |
2018年 | 2324篇 |
2017年 | 3030篇 |
2016年 | 3349篇 |
2015年 | 3358篇 |
2014年 | 5756篇 |
2013年 | 5063篇 |
2012年 | 2231篇 |
2011年 | 1390篇 |
2010年 | 3534篇 |
2009年 | 3109篇 |
2008年 | 949篇 |
2007年 | 1015篇 |
2006年 | 808篇 |
2005年 | 608篇 |
2004年 | 264篇 |
2003年 | 224篇 |
2002年 | 184篇 |
2001年 | 157篇 |
2000年 | 219篇 |
1999年 | 172篇 |
1998年 | 211篇 |
1997年 | 129篇 |
1996年 | 129篇 |
1995年 | 100篇 |
1994年 | 106篇 |
1993年 | 108篇 |
1992年 | 106篇 |
1991年 | 64篇 |
1990年 | 75篇 |
1989年 | 69篇 |
1988年 | 78篇 |
1987年 | 100篇 |
1986年 | 63篇 |
1985年 | 195篇 |
1984年 | 251篇 |
1983年 | 239篇 |
1982年 | 157篇 |
1981年 | 155篇 |
1980年 | 126篇 |
1979年 | 107篇 |
1978年 | 71篇 |
1977年 | 49篇 |
1976年 | 55篇 |
1975年 | 46篇 |
1974年 | 38篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
1.
Shengxiang Ren Jifeng Feng Shenglin Ma HuaJun Chen Zhiyong Ma Cheng Huang Li Zhang Jianxing He Changli Wang Jianying Zhou Pongwut Danchaivijitr Chin-Chou Wang Ihor Vynnychenko Kai Wang Francisco Orlandi Virote Sriuranpong Ben Li Jun Ge Thao Dang Caicun Zhou 《International journal of cancer. Journal international du cancer》2023,153(3):623-634
KEYNOTE-033 (NCT02864394) was a multicountry, open-label, phase 3 study that compared pembrolizumab vs docetaxel in previously treated, programmed death-ligand 1 (PD-L1)-positive, advanced non-small cell lung cancer (NSCLC), with most patients enrolled in mainland China. Eligible patients were randomized (1:1) to pembrolizumab 2 mg/kg or docetaxel 75 mg/m2 every 3 weeks. Primary endpoints were overall survival (OS) and progression-free survival and were evaluated sequentially using stratified log-rank tests, first in patients with PD-L1 tumor proportion score (TPS) ≥50% and then in patients with PD-L1 TPS ≥1% (significance threshold: P < .025, one-sided). A total of 425 patients were randomized to pembrolizumab (N = 213) or docetaxel (N = 212) between 8 September 2016 and 17 October 2018. In patients with a PD-L1 TPS ≥50% (n = 227), median OS was 12.3 months with pembrolizumab and 10.9 months with docetaxel; the hazard ratio (HR) was 0.83 (95% confidence interval [CI]: 0.61-1.14; P = .1276). Because the significance threshold was not met, sequential testing of OS and PFS was ceased. In patients with a PD-L1 TPS ≥1%, the HR for OS for pembrolizumab vs docetaxel was 0.75 (95% CI: 0.60-0.95). In patients from mainland China (n = 311) with a PD-L1 TPS ≥1%, HR for OS was 0.68 (95% CI: 0.51-0.89). Incidence of grade 3 to 5 treatment-related AEs was 11.3% with pembrolizumab vs 47.5% with docetaxel. In summary, pembrolizumab improved OS vs docetaxel in previously treated, PD-L1-positive NSCLC without unexpected safety signals; although the statistical significance threshold was not reached, the numerical improvement is consistent with that previously observed for pembrolizumab in previously treated, advanced NSCLC. 相似文献
2.
3.
4.
5.
6.
7.
《Journal of pharmaceutical sciences》2023,112(4):1020-1031
Stereolithography (SLA) 3D printing of pharmaceuticals suffers from the problem of light scattering, which leads to over-curing, resulting in the printing of objects that are non-compliant with design dimensions and the overloading of drugs. To minimize this problem, photoabsorbers such as tartrazine (food grade) can be used to absorb the stray light produced by scattering, leading to unintended photopolymerization. Ghost tablets (i.e., non-erodible inert matrices) were additively manufactured using SLA with varying ratios of polyethylene glycol diacrylate (PEGDA): polyethylene glycol (PEG) 300, along with tartrazine concentrations. The 3D printed ghost tablets containing maximum (0.03%) tartrazine were extremely precise in size and adhered to the nominal value of the metformin hydrochloride content. Resolution analysis reinstated the influence of tartrazine in achieving highly precise objects of even 0.07 mm2 area. Furthermore, 3D printed ghost tablets were characterized using analytical means, and swelling studies. Additionally, ghost tablets were tested for their mechanical robustness using dynamic mechanical and texture analysis, and were able to withstand strains of up to 5.0% without structural failure. The printed ghost tablets displayed a fast metformin hydrochloride release profile, with 93.14% release after 12 h when the PEG 300 ratio was at its maximum. Ghost tablets were also subjected to in vivo X-ray imaging, and the tablets remained intact even after four hours of administration and were eventually excreted in an intact form through fecal excretion. 相似文献
8.
《Journal of pharmaceutical sciences》2023,112(4):991-999
One promising approach to increase protection against infectious diseases is to use adjuvants that can selectively stimulate the immune responses. In this study, multi-epitope antigens associated with LPS loaded chitosan (LLC) as toll-like receptor agonist or mannosylated chitosan nanoparticle (MCN) as vaccine delivery system were evaluated for their ability to stimulate immune responses to Brucella infection in mice model. Our results indicated that the addition of MCN to our vaccine formulations significantly elicited IFN-γ and IL-2 cytokines and antibody titers, in comparison with the non-adjuvanted vaccine candidates. The present results indicated that multi-epitopes and their administration with LLC or MCN induced Th1 immune response. In addition, vaccine candidates containing MCN provided high percentage of protection against B. melitensis and B. abortus infection. Our results provided support to previous reports indicating that MCNs are attractive adjuvants and addition of this adjuvant to multi-epitopes antigens play an important role in the development of vaccine against Brucella. 相似文献
9.
《Journal of pharmaceutical sciences》2023,112(4):1137-1144
Pregabalin is an anti-neuropathic pain drug inhibiting the α2δ subunit of the voltage-dependent calcium channel in the spinal cord. The aim of this study is to characterize the transport mechanism of pregabalin at the blood-spinal cord barrier (BSCB) by means of in vivo experiments in rats and in vitro studies using primary-cultured rat spinal cord endothelial cells. We isolated endothelial cells by culturing rat spinal cord tissue in the presence of puromycin, and confirmed the expression of BSCB markers such as Cd31, Mdr1a, and Claudin-5. The uptake of pregabalin by primary-cultured rat spinal cord endothelial cells was sodium-independent and was significantly inhibited by L-leucine, 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid, and JPH203. These results suggest the involvement of L-type amino acid transporter (LAT) 1. LAT1 mRNA and protein was expressed in primary-cultured rat spinal cord endothelial cells, which is consistent with LAT1 expression at the BSCB. In the in vivo study, the transfer of pregabalin to rat spinal cord and brain was significantly decreased by the pre-administration of branched chain amino acids (BCAAs), which are endogenous substrates of LAT1. Our results indicate that pregabalin transport across the BSCB is mediated at least in part by LAT1 and is inhibited by plasma BCAAs. 相似文献
10.
《Journal of pharmaceutical sciences》2023,112(5):1411-1426
Repaglinide and Metformin are used to treat Type 2 diabetes. Repaglinide with poor water solubility has relatively low oral bioavailability (56%) and undergoes hepatic first-pass metabolism. The oral bioavailability of metformin HCl is also low (about 50-60%). The purpose of this study was to prepare nanoemulsion formulations containing metformin HCl or repaglinide alone or in combination and characterize them in vitro and in vivo. Nanoemulsion formulations containing metformin HCl and/or repaglinide were successfully prepared and in vitro characterized. In addition, in vivo efficacy of nanoemulsion formulations was evaluated in a streptozotocin-nicotinamide-induced diabetic rat model. Biochemical, histopathological, and immunohistochemical evaluations were also performed. The mean droplet size and zeta potential values of nanoemulsion formulations were in the range of 110.15±2.64-120.23±2.16 nm and -21.95 – -24.33 mV, respectively. The percent entrapment efficiency values of nanoemulsion formulations were in the range of 93.600%-96.152%. All nanoemulsion formulations had a PDI of ≤0.223. A statistically significant decrease was observed in the blood glucose values of the diabetic rats treated with nanoemulsion formulations containing active substance/substances, compared to diabetic rats (control) (p<0.05). Nanoemulsion formulations (especially nanoemulsion containing metformin HCl and repaglinide combination) have a better antidiabetic activity and are more effective in reducing oxidative stress caused by diabetes. 相似文献